- Home
- GOVX vs SMSI Comparison
GOVX vs SMSI Comparison
Compare GOVX & SMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- SMSI
- Stock Information
- Founded
- GOVX 2001
- SMSI 1982
- Country
- GOVX United States
- SMSI United States
- Employees
- GOVX N/A
- SMSI N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- SMSI Computer Software: Prepackaged Software
- Sector
- GOVX Health Care
- SMSI Technology
- Exchange
- GOVX Nasdaq
- SMSI Nasdaq
- Market Cap
- GOVX 16.8M
- SMSI 15.3M
- IPO Year
- GOVX N/A
- SMSI 1995
- Fundamental
- Price
- GOVX $0.60
- SMSI $0.81
- Analyst Decision
- GOVX Strong Buy
- SMSI Strong Buy
- Analyst Count
- GOVX 3
- SMSI 1
- Target Price
- GOVX $10.67
- SMSI $5.00
- AVG Volume (30 Days)
- GOVX 1.2M
- SMSI 614.3K
- Earning Date
- GOVX 11-11-2025
- SMSI 11-12-2025
- Dividend Yield
- GOVX N/A
- SMSI N/A
- EPS Growth
- GOVX N/A
- SMSI N/A
- EPS
- GOVX N/A
- SMSI N/A
- Revenue
- GOVX $6,143,044.00
- SMSI $18,658,000.00
- Revenue This Year
- GOVX N/A
- SMSI N/A
- Revenue Next Year
- GOVX N/A
- SMSI $59.48
- P/E Ratio
- GOVX N/A
- SMSI N/A
- Revenue Growth
- GOVX 1943.07
- SMSI N/A
- 52 Week Low
- GOVX $0.43
- SMSI $0.60
- 52 Week High
- GOVX $3.88
- SMSI $1.95
- Technical
- Relative Strength Index (RSI)
- GOVX 47.47
- SMSI 54.64
- Support Level
- GOVX $0.52
- SMSI $0.77
- Resistance Level
- GOVX $0.62
- SMSI $0.82
- Average True Range (ATR)
- GOVX 0.05
- SMSI 0.06
- MACD
- GOVX 0.01
- SMSI 0.00
- Stochastic Oscillator
- GOVX 71.36
- SMSI 48.42
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.